Evidence map›Paper›PMID 34540711›Full record

ArticleEuropean thyroid journal2021

Change in Practice of Radioactive Iodine Administration in Differentiated Thyroid Cancer: A Single-Centre Experience.

Ayanthi Wijewardene, Matti Gild, Carolina Nylén, Geoffrey Schembri, Paul Roach, Jeremy Hoang, Ahmad Aniss, Anthony Glover, Mark Sywak, Stan Sidhu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European thyroid journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ayanthi WijewardeneDepartment of Endocrinology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Matti GildDepartment of Endocrinology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Carolina NylénEndocrine Surgery Department, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Geoffrey SchembriFaculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
Paul RoachFaculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
Jeremy HoangFaculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
Ahmad AnissEndocrine Surgery Department, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Anthony GloverFaculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
Mark SywakFaculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
Stan SidhuFaculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
Diana LearoydFaculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
Bruce RobinsonDepartment of Endocrinology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Lyndal TaconDepartment of Endocrinology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Roderick Clifton-BlighDepartment of Endocrinology, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveOur study aimed to analyse temporal trends in radioactive iodine (RAI) treatment for thyroid cancer over the past decade; to analyse key factors associated with clinical decisions in RAI dosing; and to confirm lower activities of RAI for low-risk patients were not associated with an increased risk of recurrence.

methodsRetrospective analysis of 1,323 patients who received RAI at a quaternary centre in Australia between 2008 and 2018 was performed. Prospectively collected data included age, gender, histology, and American Joint Committee on Cancer stage (7th ed). American Thyroid Association risk was calculated retrospectively.

resultsThe median activities of RAI administered to low-risk patients decreased from 3.85 GBq (104 mCi) in 2008-2016 to 2.0 GBq (54 mCi) in 2017-2018. The principal driver of this change was an increased use of 1 GBq (27 mCi) from 1.3% of prescriptions in 2008-2011 to 18.5% in 2017-2018. In patients assigned as low risk per ATA stratification, lower activities of 1 GBq or 2 GBq (27 mCi or 54 mCi) were not associated with an increased risk of recurrence. In patients assigned to intermediate- or high-risk categories who received RAI as adjuvant therapy, there was no difference in risk of recurrence between 4 GBq (108 mCi) and 6 GBq (162 mCi).

conclusionsOur data demonstrate an evolution of RAI activities consistent with translation of ATA guidelines into clinical practice. Use of lower RAI activities was not associated with an increase in recurrence in low-risk thyroid cancer patients. Our data also suggest lower RAI activities may be as efficacious for adjuvant therapy in intermediate- and high-risk patients.

Indexed as

Adjuvant therapyATA risk stratificationRadioactive iodineThyroid cancer

Identifiers

PMID34540711
PMCPMC8406251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.